EXHIBIT 10.1 RESEARCH COLLABORATION AGREEMENT BETWEEN THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK AND B TWELVE LTD. AGREEMENT made this 19 day of August 1999 by and between THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, a...Research Collaboration Agreement • September 20th, 2005 • Kyto Biopharma Inc • Pharmaceutical preparations • New York
Research Collaboration Agreement For an Investigator Initiated ProjectResearch Collaboration Agreement • October 24th, 2022
This Agreement is based on the Alfred Health Research Collaboration Agreement for an Investigator Initiated Project. The body of this Agreement beyond the recitals should not be amended. Any proposed changes to this Agreement must be incorporated in Schedule 3 by way of Special Conditions.
RESEARCH COLLABORATION AGREEMENTResearch Collaboration Agreement • April 8th, 2022 • Georgia
THIS AGREEMENT (“Agreement”) is made and entered into as of the date of last signature below (hereinafter “Effective Date”) by and between __________________________, a [Limited Liability Company, Corporation] organized under the laws of the state of ___________ and having offices at _________________________________ (“Sponsor”) and EMORY UNIVERSITY, a Georgia non-profit corporation with offices located at 1599 Clifton Road NE, 4th Floor, Mailstop 1599/001/1AZ, Atlanta, Georgia 30322 ( “Emory”).
MELBOURNE HEALTHResearch Collaboration Agreement • December 1st, 2022 • Victoria
The Parties have agreed to collaborate on the Project in accordance with the terms and conditions set out in this Agreement.
South Dakota State University Technology Transfer Office DRAFT for Discussion purposes only. The terms offered in this draft expires thirty (30) days from the date of receipt RESEARCH COLLABORATION AGREEMENTResearch Collaboration Agreement • May 5th, 2020 • South Dakota
This Research Collaboration Agreement (the “Agreement”) is made by and between South Dakota State University, a public land grant university with its principal place of business at Box 2201, SAD 200, Brookings, South Dakota 57007-0291, (“SDSU”) and_______________, a _____________ corporation with its principal place of business at ________________________ (“XXX”) (collectively the “Parties” or individually the “Party”).
RESEARCH COLLABORATION AGREEMENTResearch Collaboration Agreement • January 5th, 2024 • ArriVent Biopharma, Inc. • Pharmaceutical preparations • New York
This RESEARCH COLLABORATION AGREEMENT (the “Agreement”) is effective as of December 21, 2021 (the “Effective Date”) by and between Aarvik Therapeutics, Inc., a company incorporated in Delaware, having a place of business at 31363 Medallion Drive, Hayward, CA 94544 (“Aarvik”), and ArriVent Biopharma, Inc., a company incorporated in Delaware, with offices located at 18 Campus Blvd. Suite 100, Newtown Square, PA 19073-3269 (“ArriVent”). ArriVent and Aarvik are referred to herein individually, as a “Party” or, collectively, as “Parties.”
CONFIDENTIALITY DEEDResearch Collaboration Agreement • December 24th, 2020 • Victoria
[Name and address of the legal entity (hospital, institution or authority) in which the Study is to being instigated (<Short title>)
Research Collaboration Agreement GuidelinesResearch Collaboration Agreement • August 17th, 2018
This Research Collaboration Agreement template is intended for investigator-initiated collaborative research projects. It has been pre-approved by all Monash Partners member organisations for these projects provided that the guidelines below are followed, the agreement is completed correctly and the legal terms are not modified except for amendments allowed by the guidelines. In these circumstances, no legal review will be required and the member organisations aim for expeditious approval in five business days or less.
RESEARCH COLLABORATION AGREEMENT BETWEEN CYTOMX THERAPEUTICS, INC. AND IMMUNOGEN, INC. JANUARY 8, 2014Research Collaboration Agreement • October 2nd, 2015 • CytomX Therapeutics, Inc. • Pharmaceutical preparations • New York
This Research Collaboration and License Agreement (the “Agreement”) is entered into as of 1 (the “Effective Date”), by and between CytomX Therapeutics, Inc., a corporation organized and existing under the laws of Delaware and having a place of business at 343 Oyster Point Blvd., Suite 100, South San Francisco, California, 94080 United States (“CytomX”) and ImmunoGen, Inc., a corporation organized and existing under the laws of Massachusetts and having a place of business at 830 Winter Street, Waltham, Massachusetts, 02451 (“ImmunoGen”). CytomX and ImmunoGen may each be referred to herein individually as a “Party” and collectively as the “Parties.”
RESEARCH COLLABORATION AGREEMENTResearch Collaboration Agreement • September 10th, 2015 • Gensight Biologics S.A. • Biological products, (no disgnostic substances) • Basel-Stadt
This Research Collaboration Agreement (the “Agreement”) having an Effective Date of March 1st, 2014, is made between the Friedrich Miescher Institute for Biomedical Research (“FMI”) located at Maulbeerstrasse 66, 4058 Basel, Switzerland, (Principal Investigator Dr. Botond Roska), and GenSight Biologics, located at 89 Rue du Fbg Saint Antoine, 75011 Paris, France (“GenSight”), (Principal Investigator Dr. Didier Pruneau), under the following terms and conditions.
RESEARCH COLLABORATION AGREEMENTResearch Collaboration Agreement • May 5th, 2020 • District of Columbia
This Agreement is between the Centers for Disease Control and Prevention (“CDC”), an agency of the U.S. Department of Health and Human Services, having offices located at 1600 Clifton Road, Atlanta, Georgia 30333, and , having a principal place of business at (“Collaborator”), (individually, a “Party”; collectively, the “Parties”).
Research Collaboration AgreementResearch Collaboration Agreement • February 18th, 2021 • New South Wales
Parties Macquarie University ABN 90 952 801 237 of North Ryde, NSW 2109 (Macquarie) Royal Prince Alfred Hospital ABN / ACN 17 520 269 052 of 50 Missenden Rd, Camperdown, NSW (Collaborating Organisation)
COGS 402 Research Collaboration AgreementResearch Collaboration Agreement • March 9th, 2019
COGS 402 is a capstone research course that enables students to exercise their skills and knowledge of computer science, linguistics, philosophy, and psychology, by gaining first-hand experience of cutting edge research that draws on one or more of these disciplines.
RESEARCH COLLABORATION AGREEMENTResearch Collaboration Agreement • September 18th, 2019 • District of Columbia
This Agreement is between the National Center for Advancing Translational Sciences (“NCATS”), which is a component of the National Institutes of Health (“NIH”), an agency of the U.S. Department of Health and Human Services, having offices located at 9800, Medical Center Drive, Rockville, MD 20850, and COLLABORATOR (“Collaborator”), having a principal place of business at ADDRESS (collectively, the “Parties”). This Agreement is neither a funding agreement as defined in 35 U.S.C. § 201(b) nor a cooperative research and development agreement authorized under the Federal Technology Transfer Act of 1986, as amended, 15 U.S.C. §§ 3710a et seq., and Executive Order 12591 of April 10, 1987. NCATS enters into this Agreement pursuant to the authority of the Public Health Services Act of 1944, as amended (42 U.S.C. § 241).
ANDResearch Collaboration Agreement • July 20th, 2000 • Gemini Genomics PLC • Services-commercial physical & biological research • New York
RESEARCH COLLABORATION AGREEMENT BETWEENResearch Collaboration Agreement • January 16th, 2017
UNIVERSITI SAINS MALAYSIA, a public institution of higher learning established under the Universities and University Colleges Act 1971, which for the purpose of this Agreement is represented by the ____________________________, with its main campus at 11800 USM, Pulau Pinang (hereinafter referred to as “USM”) of the first part;
RESEARCH COLLABORATION AGREEMENT — INVENTIONS AND MATERIALS —Research Collaboration Agreement • March 30th, 2006 • Mfic Corp • Laboratory apparatus & furniture • Massachusetts
This Agreement, effective as of September 21, 2005 (the “Effective Date”), is between the University of Massachusetts Lowell (“UML” or “Institution”), a public institution of higher education of the Commonwealth of Massachusetts, and MFIC Corporation, a Delaware corporation (“Sponsor”),
Research collaboration agreementResearch Collaboration Agreement • May 15th, 2018 • Victoria
To be used for short term, simple collaborations, without payments or material transfer between the parties. For agreements where significant amounts of equipment and payments (including valuable “in-kind” contributions are required) use a more detailed template. Do not use this agreement for NHMRC collaborations
Dated 2020Research Collaboration Agreement • September 28th, 2020
RESEARCH COLLABORATION AGREEMENTResearch Collaboration Agreement • September 29th, 2023 • Lexeo Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Research Collaboration Agreement (this “Agreement”), effective as of February 3, 2021 (the “Effective Date”), is entered into by and between Cornell University, for and on behalf of its Joan & Sanford I. Weill Medical College, a New York education corporation with offices at 1300 York Avenue, New York, NY 10065 (“WCM”), and LEXEO Therapeutics, Inc., a Delaware corporation, having an office at 430 East 29th Street, 14th Floor, New York, NY 10016 (“Company”). WCM and Company each may be referred to herein as a “Party” and together as the “Parties.”
Howard Hughes Medical Institute Host-Based Model Research Collaboration AgreementResearch Collaboration Agreement • July 19th, 2017
This Research Collaboration Agreement (the “Agreement”), having an Effective Date of _________________, is made between [Company] (the “Company”), and Howard Hughes Medical Institute (“HHMI”) and [Host Institution] (the [“University/Hospital”]) under the following terms and conditions. HHMI and the [University/Hospital] are referred to collectively in this Agreement as the “Institutions” and, unless specifically named, are treated as a single party.
RESEARCH COLLABORATION AGREEMENTResearch Collaboration Agreement • July 9th, 2012 • Stellar Biotechnologies, Inc. • Pharmaceutical preparations
STELLAR BIOTECHNOLOGIES, Inc., a corporation duly organized under and pursuant to the laws of California, USA, and having its principal offices at 321E. Hueneme Rd, #170 Port Hueneme, CA 93041, USA, (hereinafter referred to as “STELLAR”)
RESEARCH COLLABORATION AGREEMENTResearch Collaboration Agreement • March 8th, 2023
Singapore Sports Council, a body corporate established under the Singapore Sports Council Act and having its principal place of business at 3 Stadium Drive, Singapore 397630 (rebranded as “Sport Singapore” with effect from 1 April 2014 and hereinafter referred to as “SportSG” or “Sport Singapore”).
RESEARCH COLLABORATION AGREEMENT BETWEENResearch Collaboration Agreement • January 2nd, 2020
UNIVERSITI SAINS MALAYSIA, a public institution of higher learning established under the Universities and University Colleges Act 1971, which for the purpose of this Agreement is represented by its ***, with its main address at Level 6, Chancellory Building, 11800 USM, Pulau Pinang (hereinafter referred to as “USM”) of the first part;
LOGO หน่วยงาน Research Collaboration Agreement On the project entitled …..…..…..…..…..….. between Mahidol University (….Faculty / Institute ….) and (Name of Organization …..…..…..…..…..…..…..…..)Research Collaboration Agreement • January 27th, 2020
This Research Collaboration Agreement (hereinafter referred to as “Agreement”) is made at Mahidol University as of …..…..…..…..…..…..(date) by and between:
INDUSTRY RESEARCH COLLABORATION AGREEMENT RESEARCH COLLABORATION AGREEMENTResearch Collaboration Agreement • March 7th, 2024 • Cuprina Holdings (Cayman) LTD • Pharmaceutical preparations
RESEARCH COLLABORATION AGREEMENTResearch Collaboration Agreement • November 6th, 2017
This Research Collaboration Agreement (this “Agreement”) is made as of the ___ day of August, 2006, by and between C Co., Ltd. (C), having offices located at Bioventure Town, 461-58 J-Dong, Y-Gu, D, Republic of KOREA and O Therapeutics, Inc. (“Collaborator”), having a principal place of business at 993 L Drive, Suite 0, L, NJ 08648, U.S.A.
Research Collaboration Agreement GuidelinesResearch Collaboration Agreement • October 20th, 2022
This Research Collaboration Agreement template is intended for investigator-initiated collaborative research projects. It has been pre-approved by all Monash Partners member organisations for these projects provided that the guidelines below are followed, the agreement is completed correctly and the legal terms are not modified except for amendments allowed by the guidelines. In these circumstances, no legal review will be required and the member organisations aim for expeditious approval in five business days or less.
AMENDED AND RESTATED RESEARCH COLLABORATION AGREEMENT BETWEEN DIVERSA CORPORATION AND SYNGENTA PARTICIPATIONS AG January 3, 2003Research Collaboration Agreement • January 9th, 2003 • Diversa Corp • Services-commercial physical & biological research • New York
This AMENDED AND RESTATED RESEARCH COLLABORATION AGREEMENT (the “Agreement”), entered into as of January 3, 2003 and effective as of the closing of the transactions contemplated by the Transaction Agreement (as defined below) (the “Effective Date”), is made by and between Syngenta Participations AG, a corporation organized under the laws of Switzerland, with offices at CH-4002, Basel, Switzerland (“Syngenta”), and Diversa Corporation, a Delaware corporation, with offices at 4955 Directors Place, San Diego, California, 92121-1609 (“Diversa”).
Research Collaboration Agreement For an Investigator Initiated StudyResearch Collaboration Agreement • July 8th, 2016 • Victoria
This Agreement is based on the Alfred Health & Melbourne Health Research Collaboration Agreement and the Victorian Managed Insurance Authority (VMIA) Clinical Trial Research Agreement for an Investigator Initiated Study.
Research Collaboration AgreementResearch Collaboration Agreement • September 1st, 2006 • Rosetta Genomics Ltd.
This agreement (this “Agreement”) is made and entered into as of the 22 day of June, 2006 (the “Effective Date”) by and between Rosetta Genomics Ltd., a private company registered pursuant to the laws of the State of Israel, of 10 Plaut Street, Science Park, Rehovot, Israel (“Rosetta”) and Hadasit Medical Research Services and Development Ltd., a private company registered under the laws of the state of Israel, of Hadassah Medical Hospital, POB 12000, Jerusalem, Israel (“Hadasit”).
RESEARCH COLLABORATION AGREEMENTResearch Collaboration Agreement • September 1st, 2006 • Rosetta Genomics Ltd. • Delaware
THIS RESEARCH COLLABORATION AGREEMENT (this “Agreement”) is made and entered into effective as of January 31, 2006 (the “Effective Date”), by and between Rosetta Genomics, Ltd., a private company registered under the laws of the State of Israel (“Rosetta”), and Isis Pharmaceuticals, Inc., a Delaware corporation (“Isis”). Rosetta and Isis each may be referred to herein individually as a “Party,” or collectively as the “Parties.”
Research collaboration agreement Date:Research Collaboration Agreement • August 28th, 2020
specifying the extent and funding of our common research project. It does not legally bind the involved parties beyond the transfer of funding and work description, as specified in this document. By signing this Research Agreement, the following standards are to be adhered to:
RESEARCH COLLABORATION AGREEMENTResearch Collaboration Agreement • February 26th, 2024 • APRINOIA Therapeutics Inc. • Pharmaceutical preparations
THIS RESEARCH COLLABORATION AGREEMENT (“Agreement”) is made and effective as the 20th day of December, 2018 (“Effective Date”), by and between APRINOIA Therapeutics Inc. (“APN”), a company having an office at 17F, No.3, Park St., Nangang District, Taipei City 11503, Taiwan, and H. Lundbeck A/S. (“Lundbeck”), having an office at Ottiliavej 9, Valby, 2500, Denmark, and AbbVie Inc. (“AbbVie”), a company having an office at 1 N Waukegan Rd, North Chicago, IL, USA (each a “Party” and collectively, “Parties”).
CONFIDENTIAL PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT**** RESEARCH COLLABORATION AGREEMENTResearch Collaboration Agreement • January 9th, 2006 • Lpath Inc • Blank checks • England
This Research Collaboration Agreement is (“Agreement”) entered into and effective this day of August, 2005 (hereinafter the “Effective Date”), by and between
